Skip to main content
SpringerLink
Log in

Non-small cell lung cancer substantial burden

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by GlaxoSmithKline Biologicals SA.

Reference

  • Andreas S, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer : 9 Jun 2018. Available from: URL: https://doi.org/10.1016/j.lungcan.2018.06.007

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Non-small cell lung cancer substantial burden. PharmacoEcon Outcomes News 807, 25 (2018). https://doi.org/10.1007/s40274-018-5104-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5104-y

Search

Navigation